Bezartan

Bezartan

irbesartan

Manufacturer:

Duopharma Manufacturing (Bangi)

Distributor:

Duopharma Marketing
Concise Prescribing Info
Contents
Irbesartan
Indications/Uses
Essential HTN. Diabetic nephropathy in patients w/ type 2 diabetes & HTN.
Dosage/Direction for Use
Initial & maintenance dose: 150 mg once daily, may be increased to 300 mg or other anti-hypertensives can be added. Hypertensive type 2 diabetic patient Initially 150 mg once daily, titrated up to 300 mg once daily. Elderly >75 yr & haemodialysis patient Initially 75 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ aliskiren-containing drugs in patients w/ DM or renal impairment. 2nd & 3rd trimesters of pregnancy.
Special Precautions
Not recommended in primary aldosteronism & dual blockade of the renin-angiotensin-aldosterone system. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; hyperkalaemia; aortic or mitral valve stenosis or obstructive hypertrophic cardiomyopathy; ischaemic cardiopathy or CV disease. Correct vol &/or Na depletion prior to initiation. Periodic monitoring of serum K & creatinine levels, electrolytes & BP. Not recommended in combination w/ ACE inhibitors; lithium. Black patients. May affect ability to drive & use machines. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended during 1st trimester of pregnancy & lactation. Childn 0-18 yr.
Adverse Reactions
Hyperkalaemia. Dizziness, orthostatic dizziness; orthostatic hypotension; nausea/vomiting; musculoskeletal pain; fatigue; significantly increased plasma creatine kinase.
Drug Interactions
Increased hypotensive effects w/ diuretics & other antihypertensives. Higher frequency of adverse events w/ ACE inhibitors or aliskiren. Increased serum K levels w/ K-sparing diuretics, K supplements, K salt-containing substitutes. Reversible increased in serum lithium conc & toxicity. Attenuated antihypertensive effect w/ NSAIDs eg, selective COX-2 inhibitors, acetylsalicylic acid & non-selective NSAIDs.
ATC Classification
C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Bezartan FC tab 150 mg
Packing/Price
30's
Form
Bezartan FC tab 300 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in